Navigation Links
Potential new drug for some patients with treatment-resistant lung cancer
Date:10/20/2013

BOSTON The investigational drug AZD9291, a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

Mutations in the growth factor gene EGFR are present in about 10 to 15 percent of patients with the most common form of lung cancer, non-small cell lung cancer (NSCLC). Most NSCLCs harboring these EGFR mutations, called activating mutations, respond to the EGFR inhibitor drugs erlotinib and gefitinib. A majority of such cancers, however, develop resistance to these drugs within about nine to 11 months. In many cases, this is due to the cancer cells acquiring a second mutation called EGFR T790M, also known as the "resistance mutation."

"There are no approved therapies to treat lung cancer patients who develop the second mutation in the EGFR that stops the currently available medicines from working," said Susan Galbraith, M.D., Ph.D., head of the Oncology Innovative Medicines Unit at AstraZeneca. "The innovative breakthrough was finding a series of molecules that could target both the activating and resistance mutant forms of EGFR more potently than normal EGFR, which led to development of the new EGFR kinase inhibitor, AZD9291.

"AZD9291 is highly active in preclinical models and is well tolerated in animal models. It inhibits both activating and resistant EGFR mutations while sparing the normal form of EGFR that is present in normal skin and gut cells, thereby reducing the side effects encountered with currently available medicines," she added.

The AstraZeneca scientists first showed that AZD9291 potently inhibited lung cancer cells with mutant EGFR, grown in lab dishes. They then tested the drug on mice bearing lung tumors with activating mutations and mice bea
'/>"/>

Contact: Lauren Riley
lauren.riley@aacr.org
215-446-7155
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Study identifies potential treatment for lethal childhood leukemia
2. McMaster researchers find potential for new uses of old drug
3. Army researcher develops potential vaccine carrier
4. UNC study shows potential to revive abandoned cancer drug by nanoparticle drug delivery
5. New study of NIH funding allocations suggests potential efficiency gains
6. A closer look at PARP-1 reveals potential new drug targets
7. Hybrid vaccine demonstrates potential to prevent breast cancer recurrence
8. VCU Massey Cancer Center sees potential in novel leukemia treatment
9. Misuse of over-the-counter pain medication is potential health threat
10. Mutations in JAK3 gene identified in subtype of lymphoma provide potential drug target
11. Bioinformatics experts at the CNIO explore additional coding potential hidden in the human genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... GoDaddy, IX Web Hosting and Bluehost are popular ... hosting, which is the method of partitioning a ... which has the appearance and capabilities of running ... compared many professional web hosting suppliers and announced ... hosting suppliers in the global market. , GoDaddy ...
(Date:8/31/2014)... In order to celebrate the coming of autumn, Guangdong ... and launched a big promotion. Now, all the global clients ... company’s new cars are made with great materials. FODAY Automobile ... As a matter of fact, it is providing big discounts ... in need of cheap cars can visit its website for ...
(Date:8/31/2014)... Orem, UT (PRWEB) August 31, 2014 ... a number of states have proposed legislation to require ... so consumers can make informed purchasing decisions that affect ... As an industry leader advocating for stringent measures to ... launch of its “Information, Communication, Engagement” (I.C.E.) initiative with ...
(Date:8/31/2014)... Tickets for Brazil vs. Ecuador at MetLife Stadium ... This is great news for diehard soccer fans who would have ... the delight of soccer fans in the Tri-State area these two ... September 9th. , MetLife Stadium is the home field ... the National Football League. The venue opened in 2010 and has ...
(Date:8/31/2014)... UWDress.com, a renowned wedding dress manufacturer and retailer, ... elegant formal bridesmaid dresses today. Moreover, the ... quality special occasion outfits. All its current and prospective ... , Along with the greatly discounted prices, all ... promotional formal bridesmaid outfits are offered in over 20 ...
Breaking Medicine News(10 mins):Health News:GoDaddy, IX Web Hosting and Bluehost Are Awarded As Hosting Experts by Top10BestSEOHosting.com 2Health News:NutriGold Announces its I.C.E. Initiative to Educate Consumers about GMOs in Dietary Supplements 2Health News:NutriGold Announces its I.C.E. Initiative to Educate Consumers about GMOs in Dietary Supplements 3Health News:Brazil vs. Ecuador Tickets MetLife Stadium: Ticket Down Slashes Ticket Prices on Ecuador vs. Brazil Tickets in East Rutherford, NJ at the MetLife Stadium 2Health News:Elegant Formal Bridesmaid Dresses Today Unveiled By UWDress.com 2
... A steady reduction in overall cancer death rates translates ... between 1990 and 2007, according to the latest statistics ... Statistics 2011, and its companion consumer publication Cancer Facts ... all segments of the population equally. A special section ...
... poorer dental care than white Americans, even when ... understand why this is so, researchers at Columbia ... College of Dental Medicine, surveyed African American adults ... gum disease. Their findings provide insights into why ...
... death across a population has evolved in recent decades. ... attack and cancer, the role of behavioral factorsincluding smoking, ... 1990s. More recent research has begun to look ... In the first comprehensive analysis of such studies, researchers ...
... , THURSDAY, June 16 (HealthDay News) -- No ... percent of the officers from the New York Police Department,s ... on the World Trade Center, according to a new study. ... from 206 officers who responded to the attack and found ...
... (June 16, 2011) -- As many as 15 percent ... veins in the testicles. There is new evidence that ... infertility, interfere with the production of testosterone -- a ... good news too: Microsurgery can increase testosterone levels in ...
... director of Medical Student Education at Boston University ... the first physician to receive the American Association ... Career Award for her continued efforts to improve ... intellectual and developmental disabilities (I/DD). The AAIDD presented ...
Cached Medicine News:Health News:American Cancer Society report finds continued progress in reducing cancer mortality 2Health News:American Cancer Society report finds continued progress in reducing cancer mortality 3Health News:American Cancer Society report finds continued progress in reducing cancer mortality 4Health News:Why disparities in dental care persist for African-Americans even when they have insurance coverage 2Health News:Why disparities in dental care persist for African-Americans even when they have insurance coverage 3Health News:How many US deaths are caused by poverty, low levels of education and other social factors? 2Health News:Lung Health of Police Responders From 9/11 Called 'Encouraging' 2Health News:Low testosterone linked to varicoceles 2
(Date:8/29/2014)... MARLBOROUGH, Mass. , Aug. 29, 2014 /PRNewswire/ ... ) prospective, multinational study on stent removability and ... strictures has been published in the August issue ... The multinational study 1 is being conducted ... removal of fully covered self-expanding metal stents (FCSEMS) ...
(Date:8/29/2014)... Aug. 29, 2014 Medina Medical announced today ... member of the Board of Directors on August 18, ... development and commercialization experience, including over a decade of ... served as a Partner of the medical device incubator ... of two Foundry start-ups. Mr. Engelson previously served as ...
(Date:8/29/2014)... JORDAN, Utah , Aug. 29, 2014  BC ... Solutions, has acquired Polaris Medical Imaging, a leader in ... scanners. This strategic acquisition allows BC Technical to continue ... capabilities, specifically within MR and CT modalities. ... cost service," said Mark Alvarez , president and ...
Breaking Medicine Technology:Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2BC Technical Acquires Polaris Medical Imaging 2
... study broadens Phase 3 clinical program to further evaluate the ... April 15 Pfizer (NYSE: PFE ) and ... announced the initiation of a 12-month, Phase 3 clinical trial ... CONCERT, is designed to evaluate the safety and efficacy of ...
... Pharmacyclics, Inc.,(Nasdaq: PCYC ) today announced that ... study to evaluate the safety and tolerability of PCI-32765,an ... Btk,as a potential treatment for patients with relapsed or ... first Btk selective inhibitor to,be tested in humans, and ...
Cached Medicine Technology:Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimer's Disease 2Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimer's Disease 3Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimer's Disease 4Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 2Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 3Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 4Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 5
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: